It is not long since the treatment options for metastatic prostate cancer have been introduced to mankind

It is not long since the treatment options for metastatic prostate cancer have been introduced to mankind. In such revolutionary period many non-hormonal and hormonal agents like Enzalutamide have been incorporated as a vital treatment option for prostate cancer and it can be said that with the use of Enzalutamide the overall patient survival rate went up than other therapeutic agents. Being a non-steroidal 2nd generation anti-androgen it was approved for treating the metastatic CRPC, even if it was used in post-docetaxel and chemotherapy-naïve setting. In this study the pharmacological characteristics of enzalutamide, the efficacy studies which made it possible to approve this anti-androgen as well as its place in the consecutive treatment and management of metastatic prostate cancer is discussed here.

You Might Also Like
x

Hi!
I'm Alejandro!

Would you like to get a custom essay? How about receiving a customized one?

Check it out